BMPR2 and pulmonary arterial hypertension: However, if we take an isolated look at those with BMPR2 variants—a group previously reported to respond well to PGI2 inhibitors in particular [23]—it becomes apparent that there were no deaths in the patients receiving triple PAH medications.